Introduction
Celgene (NASDAQ:CELG) is a premier biotechnology company. It is a quintessential example of a pure growth stock. The company has strung together an incredibly consistent record of high earnings growth. However, although the company continues to grow earnings in excess of 20% per annum, its growth rate has slowed down due in part to its almost $98 billion market cap. Nevertheless, earnings growth in excess of 20% per annum is forecast to continue over the next three to five years at least.
Celgene: Short Business Description Courtesy S&P Capital IQ
"Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide.
It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
